Arihiro Kiyosue

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto et al. · The Lancet Diabetes & Endocrinology · 2020 · 204 citations · Full text

Pioneer 9, Diabetes Management, Diabetes +9

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 182 citations

Diabetes Management, Cardiovascular Disease, Medicine +8

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase <scp>II</scp> multicentre, randomized, double‐blind, placebo‐controlled trial

Kohei Kaku, Shin‐ichiro Inoue, Osamu Matsuoka et al. · Diabetes Obesity and Metabolism · 2012 · 134 citations

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text